Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NANS 2021: Boston Scientific Advances New Personalized Pain Therapy

Executive Summary

Boston Scientific’s WaveWriter Alpha spinal cord stimulation devices feature the proprietary FAST software for rapid, paresthesia-free pain relief of chronic pain.

You may also be interested in...



NANS 2020: Boston Scientific Expects Neuromodulation Business Rebound In 2020

At NANS, Boston Scientific presented results of the COMBO study, announced a partnership with IBM Research on digital health, and reported strong US growth in its deep brain stimulation business. Boston's C suite sees rebound for lagging neuromodulation business in 2020.

Updated: J&J Will Pay At Least $400m For Laminar To Add Stroke-Stopping Technology

Currently available catheter-based devices for left-atrial appendage closure block the opening from the left atrium into the appendage, while Laminar’s innovative approach uses rotational motion to “eliminate” the LAA.

AMA Establishes Principles For ‘Augmented Intelligence’

The American Medical Association has written a set of principles for augmented intelligence (AI) development and deployment in health care. The organization hopes these principles can shape “a consistent governance structure for advancements in health care technology.”

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT143343

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel